Personalis, Inc. (NASDAQ:PSNL) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts. Morgan Stanley Lowers Personalis (PSNL) Price Target to $10 On March 5, 2026, Personalis, Inc. (NASDAQ:PSNL) saw its price target from Morgan Stanley lowered from $11 to $10. The firm’s analyst maintained an Equal Weight rating on the stock after updating its estimates to reflect an increased 2026 net loss guidance and higher projected long-term operating expenses. In another development, ...

Core Insights - Personalis, Inc. has published the PREDICT-DNA study in the Journal of Clinical Oncology, highlighting advancements in ultrasensitive molecular residual disease testing for breast cancer [1] Company Overview - Personalis, Inc. is recognized as a leader in advanced genomics specifically for precision oncology, indicating its strong position in the healthcare sector focused on cancer treatment [1] Study Findings - The PREDICT-DNA study demonstrates that ultrasensitive ctDNA assessment can effectively evaluate and detect minimal residual disease in breast cancer patients, showcasing the potential of NeXT Personal technology [1]

Core Insights - Personalis achieved significant milestones in 2025, including Medicare coverage for breast cancer and lung cancer surveillance, which enhances the legitimacy of its tests and allows for ongoing surveillance billing [1][7][5] - The company is targeting a clinical volume of 43,000 to 45,000 tests in 2026, representing approximately 170% year-over-year growth, with over 900 oncologists currently ordering the tests [2][8] - The NeXT Personal test demonstrates high sensitivity, capable of detecting one tumor DNA fragment in a million, which facilitates earlier detection of cancer recurrence compared to standard imaging [3][5] Clinical Performance - In Q4 2025, Personalis delivered 6,183 clinical tests, marking a 41% sequential increase and a 329% year-over-year increase, with over 16,000 tests delivered throughout the year [4][8] - The company is focused on scaling its ultra-sensitive NeXT Personal MRD assay, which is currently utilized by more than 900 oncologists [8][5] Financial Overview - For 2025, Personalis reported total revenue of $69.6 million, with Q4 revenue at $17.3 million, reflecting a strategic shift away from lower-value work [6][16] - The company anticipates 2026 revenue guidance of $78 million to $80 million, with a projected net loss of approximately $105 million and cash usage of about $100 million [6][24] Research and Development - Personalis is involved in over 35 studies to support the performance of NeXT Personal, with ongoing trials demonstrating its clinical utility in various cancer types [10][12] - Landmark studies, such as the TRACERx lung cancer study and the Royal Marsden breast cancer study, have shown strong sensitivity and specificity for NeXT Personal [10][11] Biopharma Collaboration - The company reported a nearly 240% growth in biopharma MRD revenue over 2024, indicating a stabilizing environment in the biopharma sector [14][15] - For 2026, biopharma revenue is expected to be between $55 million and $56 million, with MRD revenue projected at $20 million to $21 million [15][19] Market Strategy - Personalis plans to increase its dedicated field team to enhance market share, with an estimate of 20% of 2026 test volume expected from breast cancer and 15% to 20% from lung cancer [20][5] - The introduction of a new "Real-Time Variant Tracker" report aims to assist in detecting mutations during MRD surveillance, with positive early feedback from physicians [21][5]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $17.3 million, a modest 3% increase year-over-year compared to $16.8 million in Q4 2024 [21] - Full year revenue for 2025 was $69.6 million, reflecting a transitional period for the top line [9][22] - Biopharma revenue was $10.9 million in Q4 2025, down from $12.2 million in Q4 2024, while full year biopharma revenue was $49 million compared to $51 million in 2024 [23] - Clinical revenue recognized was $0.9 million in Q4 2025 and $2 million for the full year, compared to $0.2 million and $0.8 million in 2024 respectively [24] - Gross margin was 11% in Q4 2025 and 22.7% for the full year, with expectations of margin dilution continuing into 2026 [25] Business Line Data and Key Metrics Changes - Clinical tests delivered in Q4 2025 totaled 6,183, representing a 41% sequential growth and a 329% increase year-over-year [8] - For the full year 2025, over 16,000 clinical tests were delivered, growing 394% over 2024 [8] - MRD biopharma revenue grew nearly 240% over 2024, indicating strong demand for the strategic MRD offering [9][18] Market Data and Key Metrics Changes - The clinical market for MRD testing is expected to mature into a $20+ billion opportunity, with Personalis well-positioned to capture a significant share [7] - The company achieved two Medicare coverage decisions for breast and lung cancer, validating the value of its technology [15] Company Strategy and Development Direction - The company is focused on scaling its Win-in-MRD strategy, with expectations to quadruple clinical volumes in 2026 [12] - Plans to expand commercial efforts include onboarding more oncologists and increasing the number of dedicated sales representatives [13] - The introduction of the Real-Time Variant Tracker report is aimed at enhancing the utility of the NeXT Personal test for clinicians [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying demand for MRD testing and the potential for significant growth in 2026, with revenue guidance set between $78 million and $80 million [12][29] - The company is navigating a planned decline in revenue from legacy contracts while building a diversified and sustainable high-growth engine [23] - Management highlighted the importance of clinical evidence and reimbursement decisions in driving future growth [16] Other Important Information - The company ended Q4 2025 with $240 million in cash and short-term investments, indicating a strong balance sheet [27] - Operating expenses for Q4 2025 were $27.2 million, up from $22.7 million in Q4 2024, primarily due to increased commercial and R&D investments [26] Q&A Session Summary Question: How does the recent reimbursement affect the focus of sales representatives? - Management indicated that reimbursement provides legitimacy in discussions with physicians and enhances the company's ability to invest in growth [33][35] Question: Are there any pushouts or cancellations in biopharma contracts? - Management noted that the sector is stabilizing and they have not seen significant pushouts or cancellations, with continued growth in MRD revenue [40][42] Question: What is the expected mix of reimbursed versus non-reimbursed tests in 2026? - Approximately 20% of tests are expected to come from breast cancer, 15-20% from lung cancer, and 20% from immunotherapy, with the remainder from other indications [48] Question: What is the strategy for evidence generation for new cancer indications? - The company is focused on working with key opinion leaders to establish strong clinical evidence for new indications, which is crucial for the Medicare coverage process [100]

Financial Data and Key Metrics Changes - Total company revenue for Q4 2025 was $17.3 million, a modest 3% increase year-over-year compared to $16.8 million in Q4 2024 [19] - Full year revenue for 2025 was $69.6 million, reflecting a transitional period for the top line [7][20] - Biopharma revenue was $10.9 million in Q4 2025, down from $12.2 million in Q4 2024, while full year biopharma revenue was $49 million compared to $51 million in 2024 [20] - Clinical revenue recognized was $0.9 million in Q4 2025, up from $0.2 million in Q4 2024, and $2 million for the full year 2025 compared to $0.8 million in 2024 [21] - Gross margin was 11% in Q4 2025 and 22.7% for the full year, with expectations of margin dilution continuing into 2026 [22][23] Business Line Data and Key Metrics Changes - The company delivered 6,183 clinical tests in Q4 2025, representing a 41% sequential growth and a 329% increase year-over-year [6] - For the full year 2025, over 16,000 clinical tests were delivered, growing 394% over 2024 [6] - MRD biopharma revenue grew nearly 240% over 2024, indicating strong demand for the strategic MRD offering [7][20] Market Data and Key Metrics Changes - The clinical market for MRD testing is expected to mature into a $20-plus billion opportunity, with Personalis well-positioned to capture a significant share [5] - The company achieved two Medicare coverage decisions for breast and lung cancer, validating the value of its technology [12] Company Strategy and Development Direction - The company is focused on scaling its MRD strategy, with expectations to quadruple clinical volumes in 2026 [10] - The strategic roadmap includes expanding relationships with biopharma companies and increasing the number of oncologists ordering tests [11][16] - The introduction of the Real-Time Variant Tracker report is aimed at enhancing the clinical utility of the NeXT Personal test [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong underlying demand for MRD testing and the potential for significant revenue growth in 2026, with guidance of $78 million to $80 million [10][27] - The company is navigating a planned decline in revenue from legacy contracts while building a diversified and sustainable high-growth engine [20] - Management highlighted the importance of ongoing clinical evidence generation to support reimbursement initiatives and technology development [24][100] Other Important Information - The company ended Q4 2025 with cash and short-term investments of $240 million and no debt, allowing for continued investment in growth strategies [25][26] - Operating expenses for Q4 2025 were $27.2 million, up from $22.7 million in Q4 2024, primarily due to increased commercial and R&D expenses [24] Q&A Session Summary Question: How does the recent reimbursement affect the focus of reps internally and externally? - Management indicated that reimbursement provides legitimacy in discussions with physicians and key opinion leaders, enhancing the company's position in the market [30][32] Question: Are there any pushouts or cancellations of contracts in the biopharma sector? - Management noted that the sector is stabilizing, with no significant pushouts or jolts to the business, and they are making progress in MRD [36][39] Question: What is the expected mix of reimbursed versus non-reimbursed indications in 2026? - Approximately 20% of tests are expected to come from breast cancer, 15%-20% from lung cancer, and 20% from immuno-oncology, with the remainder from other indications [46] Question: What are the expectations for adjuvant reimbursement in breast and lung cancer? - Management is focused on driving hard to submit for coverage for neoadjuvant breast cancer and colorectal cancer this year, but exact timelines are dependent on publication acceptance [95]

Core Insights - Personalis, Inc. has published a study demonstrating the effectiveness of its NeXT Personal® assay in monitoring immunotherapy responses in advanced cancers [1][2] Group 1: Study Findings - The study, led by UC San Diego Moores Cancer Center, highlights the ability of NeXT Personal to detect circulating tumor DNA (ctDNA) at ultrasensitive levels, allowing for earlier clinical interventions [3][4] - The interim analysis included 39 patients with advanced solid tumors across nine cancer types, treated with immune checkpoint inhibitors [4] - The NeXT Personal test tracks up to approximately 1,800 tumor-specific variants unique to each patient's tumor, enhancing its sensitivity [3] Group 2: Clinical Implications - Early identification of therapy response was observed, with molecular response detectable a median of 23 days after starting immunotherapy, leading to significantly longer progression-free survival for patients with early responses [7] - NeXT Personal identified molecular progression a median of 161 days before imaging in patients whose disease progressed, showcasing its potential as a predictive tool [7] - The study found that 33% of positive ctDNA detections occurred in the ultrasensitive range (below 100 PPM), which could be missed by less sensitive tests [7] Group 3: Overall Impact - Patients achieving molecular complete response (ctDNA clearance) had seven times higher overall survival compared to those who did not achieve clearance, indicating the assay's strong correlation with patient outcomes [7] - The findings reinforce the need for better tools to evaluate patient responses to immunotherapy, positioning NeXT Personal as a critical component in cancer treatment management [4]

Financial Data and Key Metrics Changes - Total company revenue for Q3 2025 was $14.5 million, a 44% decrease compared to $25.7 million in the same period last year [15][18] - Biopharma revenue was $13.2 million, representing a 16% decrease year-over-year [15][16] - Gross margin decreased to 13.2% from 34% year-over-year, primarily due to lower revenue volume and increased clinical test costs [16][17] - Net loss for Q3 was $21.7 million, compared to a net loss of $39.1 million in the prior year [18] Business Line Data and Key Metrics Changes - The company delivered 4,388 clinical tests in Q3, reflecting a 26% sequential growth and a 364% year-over-year growth [4][6] - Cumulative tests delivered to date exceeded 13,000 [6] - NeXT Personal MRD revenue accounted for more than one-third of total biopharma revenue in the quarter [16] Market Data and Key Metrics Changes - The market for ultrasensitive MRD testing is expected to mature into a $20-plus billion opportunity [5] - The company has over 700 physicians ordering NeXT Personal tests, indicating strong clinical adoption [4][8] Company Strategy and Development Direction - The company is focused on accelerating clinical adoption and driving reimbursement through clinical evidence [8][10] - Strategic partnerships with biopharma companies are being leveraged to enhance clinical trials and improve financial performance [12][70] - The company aims to achieve reimbursement coverage for multiple indications, with two targeted by the end of the year [8][34] Management's Comments on Operating Environment and Future Outlook - Management noted that while underlying demand for MRD offerings remains strong, logistical delays have impacted project timelines [7][26] - The company is optimistic about the future, expecting to achieve a higher level of revenue once reimbursement is obtained [17][60] - Management emphasized the importance of balancing test volume and margin dilution while maintaining financial discipline [17][73] Other Important Information - The company revised its full-year revenue guidance to a range of $68-$73 million, down from the previous range of $70-$80 million [20][21] - Cash and short-term investments at the end of Q3 were $150.5 million, with no debt other than small equipment loans [19] Q&A Session Summary Question: Update on large customers coming online - Both large customers have come online, contributing significantly to Q3 revenue, with one customer driving a third of MRD revenue [23] Question: Clarification on logistical delays - Logistical delays were attributed to customs issues affecting sample transport, which may impact Q4 revenue [25][26] Question: Confidence in clinical revenue guidance - Management expressed confidence in ongoing productive conversations with MolDX regarding reimbursement approvals [33][34] Question: Impact of government shutdown on MolDX - No current impact from the government shutdown has been observed on MolDX operations [47] Question: Expectations for Natera revenue - Natera's revenue is expected to be very small in Q4, with no significant contributions anticipated in the following year [76][78] Question: Timeline for TracerX study publication - The TracerX study is expected to be published in the next quarter, showcasing strong performance with NeXT Personal [79] Question: Insights on MRD test growth - Growth is driven by deeper penetration within existing accounts rather than solely acquiring new physician orders [92]

Company Overview - Personalis (PSNL) shares increased by 20.5% to $10.28 in the last trading session, with a notable trading volume, and have gained 48.9% over the past four weeks [1][2] - The company specializes in contract research and genomic information, and is part of the Zacks Medical - Generic Drugs industry [4] Recent Developments - The surge in share price is attributed to new data from AstraZeneca's late-stage lung cancer study (LAURA), which utilized Personalis' NeXT Personal molecular residual disease (MRD) test, showing a median lead time of five months in detecting MRD progression [2] - The consensus EPS estimate for the upcoming quarterly report is a loss of $0.28 per share, reflecting a year-over-year increase of 56.3%, while revenues are expected to be $13.7 million, down 46.7% from the previous year [3] Market Position - The consensus EPS estimate for Personalis has remained unchanged over the last 30 days, indicating a potential stabilization in earnings expectations [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [4]

Core Insights - Pancreatic cancer is highly lethal with a five-year survival rate of only 12%, and current first-line chemotherapy regimens show variable efficacy [1][10] - Tempus AI Inc. has developed PurIST, an RNA-based algorithm that classifies pancreatic ductal adenocarcinoma (PDAC) tumors into "classical" or "basal" subtypes, addressing the need for robust biomarkers in therapy selection [2][10] - The global pancreatic cancer treatment market is projected to reach $5.84 billion by 2030, growing at a CAGR of 12.3% from 2025 to 2030, positioning Tempus' PurIST for significant growth [3] Company Developments - Tempus AI recently presented the largest real-world evidence supporting the integration of PurIST into clinical care for advanced PDAC, demonstrating its role in personalizing first-line therapy [4][5] - The findings from the study published in JCO Precision Oncology establish PurIST as both a prognostic and predictive biomarker, enhancing the likelihood of improved survival for patients [5][10] Market Performance - Tempus AI shares have increased by 67.4% over the past year, outperforming the industry growth of 21.4% and the S&P 500's 19.4% [9] - The company currently trades at a forward Price-to-Sales (P/S) ratio of 9.56X, significantly higher than the industry average of 5.88X, indicating a potentially expensive valuation [11] Financial Estimates - Recent estimates indicate a slight downward adjustment in Tempus AI's loss per share for 2025, moving from -0.14 to -0.16 over the past 30 days [12][13]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $16.8 million, a 15% decrease from $19.7 million in Q4 2023, primarily due to lower volume from Natera and the VA MVP program [38][39] - Full year 2024 revenue was $84.6 million, representing a 15% increase compared to $73.5 million in 2023, driven by a 60% year-over-year growth in biopharma revenue [13][43] - Gross margin for Q4 2024 was 27.1%, up from 26.5% in Q4 2023, while full year gross margin improved to 31.7% from 24.8% in 2023 [40][44] - Net loss for Q4 2024 was $16.4 million, reduced from $26.6 million in Q4 2023, and the full year net loss was $81.3 million compared to $108.3 million in 2023 [42][47] Business Line Data and Key Metrics Changes - Biopharma revenue increased by 60% year-over-year, significantly contributing to overall revenue growth, particularly from Moderna's Phase 3 melanoma trial [13][43] - The company delivered 1,441 molecular tests in Q4 2024, a 52% increase from 945 tests in Q3 2024, indicating strong demand for the NeXT Personal test [21] Market Data and Key Metrics Changes - The MRD testing market is projected to mature into a $20 billion market, with Personalis positioned for success through its ultra-sensitive MRD test, NeXT Personal [8] - The company expects to achieve Medicare reimbursement for at least two indications in 2025, focusing on breast cancer, lung cancer, and immunotherapy monitoring [24][25] Company Strategy and Development Direction - The company has laid out a multiyear strategy focused on winning in the MRD testing market, with plans to ramp up clinical volume and achieve reimbursement [19][35] - A long-term extension of the agreement with Moderna is expected to be a key driver of revenue growth over the next decade [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, anticipating continued test volume growth of 30% to 40% each quarter until reimbursement is achieved [22][35] - The company aims to deepen clinical evidence and achieve reimbursement for its tests, with a robust pipeline of over 20 studies in progress [26][30] Other Important Information - The company raised approximately $115 million in 2024 through strategic investments, enhancing its liquidity position with $185 million in cash at year-end [18][48] - Operating expenses for the full year 2024 were reduced to $95.1 million from $128.1 million in 2023, primarily due to headcount reductions [45] Q&A Session Summary Question: Should we read into the guidance that there are continuing Natera revenues? - The guidance includes revenue from both Natera and other enterprise customers, with the VA contract contributing approximately $7.5 million to $8 million [54] Question: What is the number of customers using the NeXT Dx test and the reorder rate? - Approximately 300 doctors used the test last quarter, with a high retention rate in the high 90s [56][58] Question: How should we think about the phasing of the top line for 2025? - Revenue is expected to be split approximately half in the first half and half in the second half of 2025, with biopharma revenue skewed towards the second half [63] Question: What is the expected impact on gross margins due to unreimbursed tests? - The gross margin guidance for 2025 is 21% to 23%, with significant headwinds expected from unreimbursed test costs [66] Question: Will the company look to the capital markets this year? - The company has sufficient capital to reach cash flow break-even and will evaluate the need for additional capital based on business developments [83]